Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

$846,595 $661,982

CEPHALON, INC. AND SUBSIDIARIES

Reconciliation of Projected GAAP Basic Income per Common Share

to Basic Adjusted Income Per Common Share Guidance

(Unaudited)

Twelve Months Twelve Months

Ended Ended

December 31, 2008 December 31, 2009

Projected GAAP basic income per common

share $4.41 - $4.51 $4.95 - $5.05

Amortization of current intangibles $1.48 - $1.48 $1.36 - $1.36

Accelerated depreciation adjustment-

CIMA $0.10 - $0.10 $0.09 - $0.09

Accelerated depreciation adjustment-

Mitry-Mory $0.10 - $0.10 $0.24 - $0.24

Cost of goods sold adjustments $0.38 - $0.38 $- - $-

Research and development adjustments $0.12 - $0.12 $- - $-

Selling, general and administrative

adjustments $0.44 - $0.44 $- - $-

Settlement reserve adjustments $0.11 - $0.11 $- - $-

In-process research and development

adjustment $0.15 - $0.15 $- - $-

Restructuring adjustments $0.12 - $0.12 $0.07 - $0.07

Interest expense adjustment $0.17 - $0.17 $- - $-

Interest expense adjustment for

APB 14-1 $- - $- $0.63 - $0.63

Tax effect of pre-tax adjustments at

the applicable tax rates $(2.38)- $(2.38) $(0.84)- $(0.84)

Basic adjusted income per common share

guidance $5.20 - $5.30 $6.50 - $6.6
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 PrimeSource Building Products, ... selected SoundConnect to support their communication ... audio and web conferencing platform GlobalMeet powered by ... employees’ needs. SoundConnect delivers award winning “results ... Building Products will be utilizing GlobalMeet powered ...
(Date:8/27/2014)... , Aug. 27, 2014 Rhythm, a biopharmaceutical ... genetic deficiencies that result in metabolic disorders, announced today ... S-1 with the U.S. Securities and Exchange Commission (SEC) ... of its common stock. The number of shares to ... have not yet been determined. Citigroup and ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The Global ... in-depth study on the current state of the Trifluoroacetic ... provides a basic overview of the industry, including definitions, ... Chinese domestic market analysis are provided with a focus ... market. A comparison between the international and Chinese situation ...
(Date:8/27/2014)... 2014 “We are honored to be ... Ven Thangaraj, CEO of Radiant Sage. “We are offering ... the imaging corelab market to a different level. ... organizations to efficiently and effectively manage the massive amounts ... be analyzed and read by trained physicians. Being recognized ...
Breaking Biology Technology:PrimeSource Chooses SoundConnect as Collaboration Provider 2Rhythm Files Registration Statement for Proposed Initial Public Offering 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2
... Plexus Corp. (Nasdaq: PLXS ) announced today ... automated screening system for the pre-processing of human papillomavirus (HPV) ... to a current manual process, through sophisticated robotic motions. ... HPV; a virus that has an established link to cervical ...
... general health and self-care management by using simple tools ... May 28 Roche, the maker of ACCU-CHEK(R) blood ... availability of two new tools that can help patients ... impact on their blood glucose levels, giving them greater ...
... ISELIN, N.J., May 28 SyntheMed, Inc. (OTC ... the development and commercialization of anti-adhesion products, announced ... film for the reduction of adhesions following cardiac ... Goods Administration for use in all patients who ...
Cached Biology Technology:Plexus Awarded Development Contract With QIAGEN 2Plexus Awarded Development Contract With QIAGEN 3Plexus Awarded Development Contract With QIAGEN 4Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better 2Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better 3SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R) 2
(Date:8/28/2014)... healthier for your neighbors than traditional cigarettes, but ... a new study from USC. , Scientists studying ... decrease in exposure to harmful particles, with close-to-zero ... to some harmful metals in second-hand e-cigarette smoke ... tobacco smoke contains high levels of polycyclic aromatic ...
(Date:8/28/2014)... Access to Research Careers) Program has announced the ... America,s 27th Annual Mouse Molecular Genetics Conference from ... Grove, California. These awards are meant to ... scientists from underrepresented groups into the mainstream of ... participation of young scientists at the Genetics Society ...
(Date:8/28/2014)... delivering compounds that could positively impact the ... be possible, thanks to researchers in Penn ... vaginal suppository made from the seaweed-derived food ... drug Tenofovir provides a woman-initiated, drug-delivery vehicle ... sexually transmitted infections during unprotected heterosexual intercourse, ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3
... scientists from the National Human Genome Research Institute (NHGRI), ... reported it has identified six more genetic variants involved ... number of genetic risk factors associated with increased risk ... by the new study had previously been suspected of ...
... crosses between nerve cells. Changes in the strength of ... both memory formation and learning, and help determine how ... Dubnau, Ph.D., leads a CSHL neuroscience lab that studies ... team had previously identified a group of fly genes ...
... -Oceanic shark populations worldwide are declining from destructive high-seas ... shark products (mainly fins and meat), with some shark ... recovering, according to a comprehensive new book co-edited by ... ( www.pewoceanscience.org ), published by Blackwell Publishing, and being ...
Cached Biology News:Major collaboration uncovers surprising new genetic clues to diabetes 2Major collaboration uncovers surprising new genetic clues to diabetes 3CSHL scientists identify a mechanism that helps fruit flies lock-in memories 2Oceanic sharks worldwide at serious risk from high-seas fishing, rising demand for shark products 2Oceanic sharks worldwide at serious risk from high-seas fishing, rising demand for shark products 3Oceanic sharks worldwide at serious risk from high-seas fishing, rising demand for shark products 4
...
...
... Serum • Rhesus serum is collected from ... years of age. Available Anticoagulants: ... (Na) N-06: K2EDTA N-08: ... N-03: Alsevers N-05: ACD ...
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
Biology Products: